3 citations
,
July 2020 in “Frontiers in Cell and Developmental Biology” This study found that the purified compound VB1 from Vitex negundo seeds may reduce UVA-induced skin aging by targeting MAPK1 and demonstrated its potential in mice.
3 citations
,
November 2018 in “Oncology issues” This article discusses the emerging field of supportive oncodermatology, which collaborates between oncology and dermatology to address skin-related side effects of cancer treatments, and reports no new clinical results.
This study introduced Cadd4, a peptide-based degrader developed using computer-aided drug design, which effectively reduced PCSK9 levels and increased LDL receptor expression, resulting in decreased plasma cholesterol and LDL-C levels in hypercholesterolemic mice, without liver toxicity.
2 citations
,
May 2025 in “Frontiers in Pharmacology” In this study, analysis of FDA data revealed a substantial risk of dermatologic adverse events with aromatase inhibitors, especially anastrozole and exemestane, highlighting the importance of dermatologic monitoring during such therapies.
2 citations
,
April 2025 in “Cureus” In this study, among Indian patients with triple-negative breast cancer, Ki-67 expression levels were high but not significantly associated with treatment response to a neoadjuvant docetaxel-carboplatin regimen, which showed complete clinical, imaging, and pathological response rates of 39.13%, 34.78%, and 47.61%, respectively.
2 citations
,
March 2025 in “International Journal of Advanced Science and Engineering” This review highlights that nanoemulsions, especially those with droplet sizes under 200 nm, show promise in pharmaceuticals and cosmetics by improving drug stability, bioavailability, and reducing side effects, with potential applications in CNS diseases, cancer treatments, and skincare products.
2 citations
,
January 2018 in “Elsevier eBooks” Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.
2 citations
,
January 2012 in “InTech eBooks” This chapter provides an overview of chemotherapy-induced alopecia, discussing its biological and clinical aspects, current experimental models and treatments, and calls for improved understanding to prevent and manage it.
1 citations
,
March 2025 in “Biomedical Journal of Scientific & Technical Research” This publication overview describes the Biomedical Journal of Scientific & Technical Research's rigorous peer review process and their focus on genetic, biomedical, and technical knowledge research within an open access format, but does not report specific study results.
1 citations
,
January 2025 in “Frontiers in Oncology” This review highlights REV7's crucial roles in maintaining genome stability, its implication in several cancers, and its association with poor prognoses and treatment resistance, while also noting that REV7 suppression may improve chemotherapy sensitivity.
1 citations
,
November 2024 in “Frontiers in Immunology” This study provides an analysis of global publications on TLS, offering insights into the role of TLS in immunotherapy and suggesting future research directions.
1 citations
,
October 2024 in “Journal of King Saud University - Science” In this in vitro study, extracts from Tridax procumbens demonstrated potential antioxidant and anticancer activity against various human cancer cell lines, with notable efficacy in specific fractions.
1 citations
,
May 2022 in “Голова и шея.” This study found that using a collagen sponge with lincomycin reduced inflammation and pathogen presence in alveolar osteitis more effectively than iodoform gauze, leading to faster socket healing.
1 citations
,
May 2022 in “Голова и шея.” This study observed a strong positive association between the expression of the p53 protein and the appearance of dark neurons in the hippocampus of rats following experimental septoplasty, suggesting p53's potential neuroprotective role alongside its activation of damaged neurons.
1 citations
,
May 2022 in “Голова и шея.” This study concluded that the anesthesia protocol using fentanyl, propofol, cisatracuria besylate, tranexamic acid, atropine, and metoclopramide resulted in the least pain during septoplasty.
1 citations
,
May 2022 in “Голова и шея.” This study found that photobiomodulation after septoplasty reduced pain and inflammatory response, leading to less pronounced changes in autonomic nervous system activity compared to patients who did not receive this treatment.
1 citations
,
May 2022 in “Голова и шея.” This study found that a nanobiotechnological method may allow express diagnostics of ocular adnexal tumors by comparing the level of biogenic silver nanoparticle formation between malignant and benign tumors.
1 citations
,
May 2022 in “Голова и шея.” In this study, researchers found an increase in daily physical activity during the COVID-19 pandemic among students, with a notable rise in leisure walking and transportation, but also increased weekday sedentary behavior in men.
1 citations
,
May 2022 in “Голова и шея.” This study evaluated the quality of life and mental health of patients after moderate traumatic brain injury, reporting changes in physical, mental, and social health as measured by various health scales.
1 citations
,
May 2022 in “Голова и шея.” This study found that septoplasty simulation in rats led to decreased exploratory behavior and anxiety, suggesting a link between postoperative stress and changes in the hippocampal region.
1 citations
,
March 2019 in “Actas Dermo-Sifiliográficas” This review discusses the adverse effects on hair associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for comprehensive documentation of these effects.
1 citations
,
December 2013 in “Urological Science” This case report documents a 59-year-old man in Taiwan who developed breast cancer while undergoing finasteride therapy for benign prostate hyperplasia, marking a rare side effect.
1 citations
,
January 2010 in “Elsevier eBooks” Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.
June 2026 in “Pathology & Oncology Research” In this study, the Orbis PAXMAN® scalp cooling system showed effectiveness and good tolerability in preventing chemotherapy-induced hair loss in breast cancer patients, particularly those receiving anthracycline-free chemotherapy, though the presence of comorbidities was linked to a higher risk of severe alopecia.
June 2026 in “Current Oncology Reports” This review highlights the potential of Sacituzumab Tirumotecan, an antibody-drug conjugate, in treating gynecologic cancers, with ongoing Phase III trials indicating a manageable safety profile and future results expected to shed light on its effectiveness in improving survival and response rates.
May 2026 in “Scientific Reports” In this study, researchers overexpressed Lrig3 in mouse skin and observed hair loss linked to changes in skin protein profiles and signaling pathways, suggesting a potential role for Lrig3 in maintaining skin homeostasis.
March 2026 in “Korean Journal of Clinical Pharmacy” In this review, researchers discuss 50 novel drugs approved by the FDA in 2024, highlighting key agents like vadadustat for anemia in chronic kidney disease and donanemab for Alzheimer’s, and focusing on their roles in pharmacy education and clinical decision-making.
March 2026 in “Journal of Cancer Survivorship” This review highlights the potential for physical exercise to reduce treatment toxicity and modification rates in patients with metastatic colorectal cancer receiving systemic treatments, suggesting benefits for survival outcomes; it recommends further trials to confirm these findings.
March 2026 in “Cancer Diagnosis & Prognosis” In this study, researchers used a patient-reported outcome questionnaire to assess long-term adverse effects in breast cancer patients undergoing chemotherapy, finding persistent symptoms like neuropathy, dysgeusia, insomnia, and nail loss. Peripheral neuropathy was notably prolonged in those receiving anthracycline- and taxane-based regimens compared to docetaxel/cyclophosphamide.
February 2026 in “MedBA Medicine” This study identified potential new adverse drug reaction signals for erlotinib, used in lung and pancreatic cancer treatment, by analyzing a large dataset of case reports, indicating further clinical studies are necessary to confirm these findings.